Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise

Harry H. Yoon; Haidong Dong; Qian Shi

doi:10.1158/1078-0432.CCR-22-0932

Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise

Research output: Contribution to journal › Article › peer-review

Abstract

Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments.

Original language	English (US)
Pages (from-to)	3173-3175
Number of pages	3
Journal	Clinical Cancer Research
Volume	28
Issue number	15
DOIs	https://doi.org/10.1158/1078-0432.CCR-22-0932
State	Published - Aug 1 2022

ASJC Scopus subject areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-22-0932

Cite this

@article{dd120b8366324e72968e56b103b7dc66,

title = "Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise",

abstract = "Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments.",

author = "Yoon, {Harry H.} and Haidong Dong and Qian Shi",

note = "Publisher Copyright: {\textcopyright} 2022 American Association for Cancer Research.",

year = "2022",

month = aug,

day = "1",

doi = "10.1158/1078-0432.CCR-22-0932",

language = "English (US)",

volume = "28",

pages = "3173--3175",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "15",

}

TY - JOUR

T1 - Impact of PD-1 Blockade in Nonresponders

T2 - Pitfalls and Promise

AU - Yoon, Harry H.

AU - Dong, Haidong

AU - Shi, Qian

PY - 2022/8/1

Y1 - 2022/8/1

N2 - Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments.

AB - Exploratory analysis of a phase III trial in esophageal cancer found that the patients who most contributed to an overall survival benefit from PD-1 blockade were not responders, but non-responders. The analysis has limitations but may have implications for investigating the optimal timing of immunotherapy relative to other treatments.

UR - http://www.scopus.com/inward/record.url?scp=85135596821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85135596821&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-22-0932

DO - 10.1158/1078-0432.CCR-22-0932

M3 - Article

C2 - 35671005

AN - SCOPUS:85135596821

SN - 1078-0432

VL - 28

SP - 3173

EP - 3175

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 15

ER -

Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this